Pharmacist Medication Regimen Review Irregularities Not Sent and Acted Upon
Summary
The facility did not ensure that irregularities identified by the consultant pharmacist during Medication Regimen Review were sent to the attending physician and acted upon for 2 of 5 residents reviewed for unnecessary medications. The facility policy titled “Addressing Medication Regimen Review Irregularities (Pharmacist Recommendations)” stated that the pharmacist must report irregularities to the attending physician, medical director, and DON, and that the attending physician must document review and any action taken in the resident’s record. For one resident with chronic kidney disease stage 3, COPD, morbid obesity, asthma, dysphagia, anxiety disorder, major depressive disorder, hypertension, gout, GERD, and hereditary and idiopathic neuropathy, the MAR showed alprazolam 0.25 mg every 8 hours as needed for anxiety starting 8/12/25. The pharmacist’s 8/22/25 review noted the resident had used alprazolam 10 times since it started and documented that PRN psychotropic orders require no more than 14 days unless clinical rationale and a specific duration are provided. The recommendation was to discontinue alprazolam or provide rationale for continued PRN use, but the form was not checked. The physician response was dated 9/23/25 and stated the resident continued to take alprazolam PRN daily and the medication should be scheduled daily. The DON stated the pharmacy sends her an email and she notifies the NP or doctor. For another resident with autistic disorder, repeated falls, unspecified intellectual disabilities, epilepsy, mood disorder, anxiety disorder, and gastrostomy, the admission MDS documented severely impaired cognitive skills, memory deficits, moderate depressive symptoms, behaviors interfering with care, rejection of care, and wandering. The pharmacist’s July 2025 review identified PRN lorazepam and temazepam since admission and recommended discontinuing or providing rationale for continued PRN use, but neither option was checked. A second July 2025 review identified duplicate olanzapine and high-dose quetiapine, along with multiple other psychotropic medications, and recommended a gradual dose reduction or continuation rationale; neither option was checked. A September 2025 review identified possible transcription error with valproate dosing, scheduled lorazepam 1 mg every 4 hours, olanzapine 30 mg at bedtime, and temazepam 30 mg at bedtime, and again neither recommendation/option was checked. A handwritten note stated the review was discussed with the MD by phone, and the NHA documented medication changes and clarifications after the pharmacist reports.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.